Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.

Source:http://linkedlifedata.com/resource/pubmed/id/12384405

Blood 2002 Nov 1 100 9 3101-7

Download in:

View as

Triples

General Info

PMID
12384405